Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Tactile Systems Technology (TCMD) and Danaher (DHR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Quest Diagnostics (DGX – Research Report), Tactile Systems Technology (TCMD – Research Report) and Danaher (DHR – Research Report).

Quest Diagnostics (DGX)

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Quest Diagnostics today. The company’s shares closed last Tuesday at $136.70.

According to TipRanks.com, Goonewardene is a 1-star analyst with an average return of -2.2% and a 32.8% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Allogene Therapeutics, and Mersana Therapeutics.

Quest Diagnostics has an analyst consensus of Hold, with a price target consensus of $144.08, a 6.7% upside from current levels. In a report issued on April 9, Robert W. Baird also maintained a Hold rating on the stock with a $138.00 price target.

See the top stocks recommended by analysts >>

Tactile Systems Technology (TCMD)

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology, with a price target of $25.00. The company’s shares closed last Tuesday at $14.57.

According to TipRanks.com, Maeder is a 5-star analyst with an average return of 19.5% and a 59.9% success rate. Maeder covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Intuitive Surgical, and Vicarious Surgical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tactile Systems Technology with a $21.00 average price target.

Danaher (DHR)

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on Danaher, with a price target of $235.00. The company’s shares closed last Tuesday at $253.11.

According to TipRanks.com, Arias is ranked 0 out of 5 stars with an average return of -9.4% and a 38.2% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Guardant Health, and Mettler-Toledo.

Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $275.50, an 8.2% upside from current levels. In a report issued on April 10, Barclays also maintained a Hold rating on the stock with a $260.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DGX:

• Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
• Quest Diagnostics raises FY24 adjusted EPS view $8.72-$8.97 from $8.60-$8.90
• Quest Diagnostics reports Q1 adjusted EPS $2.04, consensus $1.85
• Notable companies reporting before tomorrow’s open
• Quest Diagnostics launches blood biomarker test for Alzheimer’s diagnosis